Short answer
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an 8-K current report with the SEC on August 20, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Clover Health published responses to selected shareholder questions following its second-quarter 2026 earnings announcement.
CLOVER HEALTH INVESTMENTS, CORP. /DE 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Clover Health published responses to selected shareholder questions following its second-quarter 2026 earnings announcement
- Exhibit 99.1 contains the supplemental questions and management’s written responses
- Disclosure signals investor-relations engagement, with potential clarification of issues raised around second-quarter results
Item EX-99.1 · Exhibit EX-99.1
- CA-managed year-3 members generate approximately $155 PMPM more insurance gross profit than year-1 members
- CA-managed members show approximately 18% better MCR in year 3, supporting Clover’s cohort-maturation earnings thesis
- 4.5-Star ratings apply to the 2027 payment year, providing incremental flexibility beyond underlying cohort improvement
- Approximately 49% of membership remains in years one and two, leaving substantial maturation upside but retaining execution risk
- New Jersey individual non-SNP market share is approximately 31%, favoring density-led growth over near-term geographic expansion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CLOVER HEALTH INVESTMENTS, CORP. /DE 8-K filings
Get the next CLOV 8-K as it lands
Follow CLOV for push alerts, or ask the research agent what this filing means.